After Hours Summary: CPXX +346.4%, CTIC +30.8%, IMMU -15.1%, NVIV -10.9% following newsAfter Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: SZYM +31.6% (also announces multi-year global supply agreement with Unilever), BORN +23.5%, AMPH +14.9%, ESI +14.1%, INGN +12.7%, BDE +12.4%, ARTX +5.1%, PFSW +4.9%, VSLR +4.3%,
Companies trading higher in after hours in reaction to news: CPXX +346.4% Announced 'positive' results from Phase 3 trial of VYXEOS Liposome for Injection in patients with high-risk acute myeloid leukemia. CTIC +30.8% Provides update regarding the availability of pacritinib to certain patients with myelofibrosis, says FDA has expressed interest in allowing patients to continue receiving pacritinib under a single patient IND program. OUTR +10.5% To explore strategic and financial alternatives; increases quarterly dividend to $0.60/share from $0.30/share. BCRX +5.4% D.E. Shaw & Co discloses 5.1% passive stake. AVP +2.5% To reduce headcount by 2,500 positions as part of 3-year plan.
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: MNKD -15.8%, DCO -7.6%, DOV -2.1%, JMBA -2%, KANG -1%,
Companies trading lower in after hours in reaction to news: IMMU -15.1% To terminate the Phase 3 PANCRIT-1 trial with yttrium-90-labeled clivatuzumab tetraxetan in patients with metastatic pancreatic cancer. NVIV -10.9% Commences an underwritten public offering of common stock for unspecified amount. APPY -5.8% Terminates proposed transactions with Strand Life Sciences. TCON -5.4% Initiates phase 1B study of TRC105 in patients with lung cancer. CBPX -3.9% Announces 4.5 mln share secondary common stock offering by selling shareholders & 900,000 share repurchase. PRTY -2.7% Acquires Festival SA for ~$5 mln.